PDHA1 and neoplasm: In particular, CPI613, a lipoic acid analog that inhibits PDHA1 and OGDH, has been shown to dramatically attenuate the progression of melanoma and improve the therapeutic efficacy of anti-PD-1 against this tumor [14].